OTLK - Outlook Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

58.55M

Cash

33.71M

Avg Qtr Burn

-10.12M

Short % of Float

20.18%

Insider Ownership

60.70%

Institutional Own.

10.64%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Details Eye disease , Wet age-related macular degeneration	BLA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Details Eye disease , Wet age-related macular degeneration	BLA FDA meeting	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Details Diabetes, Eye disease , Human herpesvirus 6, Epstein-Barr virus, Adenovirus, BK virus, Cytomegalovirus, Diabetic macular edema	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Details Eye disease	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.